IDEXX Laboratories, Inc. $IDXX Position Reduced by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 544,185 shares of the company’s stock after selling 13,001 shares during the period. Dimensional Fund Advisors LP owned about 0.68% of IDEXX Laboratories worth $347,641,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in IDXX. Blalock Williams LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth about $590,000. New York State Common Retirement Fund boosted its holdings in shares of IDEXX Laboratories by 6.8% during the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after purchasing an additional 3,820 shares during the period. Mediolanum International Funds Ltd grew its position in IDEXX Laboratories by 14.5% during the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after purchasing an additional 4,909 shares in the last quarter. Principal Financial Group Inc. grew its position in IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after purchasing an additional 187,967 shares in the last quarter. Finally, Orion Porfolio Solutions LLC increased its stake in IDEXX Laboratories by 116.6% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock valued at $5,749,000 after buying an additional 5,770 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of research reports. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. BTIG Research dropped their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, UBS Group cut their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $783.33.

Insider Buying and Selling

In other news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the transaction, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director owned 648 shares of the company’s stock, valued at approximately $407,345.76. The trade was a 69.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last quarter. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 4.6%

Shares of IDXX stock opened at $618.92 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average is $668.54 and its two-hundred day moving average is $668.40. The company has a market cap of $49.28 billion, a PE ratio of 47.35, a price-to-earnings-growth ratio of 3.94 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the firm posted $2.53 earnings per share. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.